Company Focus
Novartis
Latest Novartis News
Pharmaceutical
Under the Medicare Drug Price Negotiation Program (Negotiation Program), the US Centers for Medicare & Medicaid Services (CMS) directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. 16 March 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Purple Biotech focuses on immuno-oncology and targeted cancer therapies designed to enhance immune responses against solid tumors.
Latest News & Features of interest to Novartis
Biotechnology
Shares of US biotech CytomX Therapeutics’ rocketed 53% to $7.16, after the leader in the field of masked, conditionally activated biologics, today announced positive Phase I expansion data for its EpCAM PROBODY ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC. 16 March 2026
Pharmaceutical
The Phase III study FIND-CKD investigating the efficacy and safety of Kerendia (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) - has met its primary endpoint. 16 March 2026
Pharmaceutical
Europe is achieving better cancer outcomes without cancer overwhelming health budgets, according to the Comparator Report on Cancer in Europe 2025 by the Swedish Institute for Health Economics (IHE). 16 March 2026
Pharmaceutical
Under the Medicare Drug Price Negotiation Program (Negotiation Program), the US Centers for Medicare & Medicaid Services (CMS) directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. 16 March 2026
Biotechnology
Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only interleukin (IL)-17A inhibitor for this population. 16 March 2026
Biotechnology
AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (EU) for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. 16 March 2026
Pharmaceutical
Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as an initial treatment option for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) in the latest National Cancer Comprehensive Network) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 5.2026), updated on March 13, 2026. 15 March 2026
Pharmaceutical
Important research news last week included Vertex announcing positive Phase III results for its povetacicept in immunoglobulin A nephropathy. And, BridgeBio reported positive Phase III results for BBP-418 in muscular dystrophy. Also of note, German biotech BioNTech revealed that its co-founders were planning to leave the company, along with 2025 financial results. 15 March 2026
Biotechnology
Australian biotech Immutep’s shares plummeted 88.6% to A$0.045 today, after it announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (efti) in patients in first-line non-small cell lung cancer (NSCLC) has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol. 13 March 2026
Pharmaceutical
armaceutical Development & Commercialization and its parent Japan-based Otsuka Pharmaceutical have announced new open-label extension study data for repinatrabit (JNT-517), demonstrating early and clinically-meaningful reductions in blood phenylalanine (Phe) levels (-67% mean change from baseline) in adolescents with phenylketonuria (PKU).
13, 2026 13 March 2026
Latest In Brief for Novartis
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze